UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 12b-25

SEC FILE NUMBER
   

000-54986
     
   

CUSIP NUMBER
 

NOTIFICATION OF LATE FILING

03939W208

 

(Check one):

☐ Form 10-K

☐ Form 20-F

☐ Form 11-K

☒ Form 10-Q

☐ Form 10-D
 

☐ Form N-SAR

☐ Form N-CSR

      

 

 

For Period Ended: December 31, 2023
 

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

☐ Transition Report on Form N-SAR
   
 

For the Transition Period Ended:

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I - REGISTRANT INFORMATION

 

Arch Therapeutics, Inc.

Full Name of Registrant
 

Almah, Inc.

Former Name if Applicable
 

235 Walnut Street, Suite 6

Address of Principal Executive Office (Street and Number)
 

Framingham, Massachusetts 01702

City, State and Zip Code

 

 
 

 

PART II - RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

 

(a)

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     

☒

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
 

(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III - NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

Arch Therapeutics, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 by the prescribed due date without unreasonable effort or expense because of the circumstances described below.

 

The Company is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 by the prescribed due date. Additional time was needed for the Company to file its Annual Report on Form 10-K for the year ended September 30, 2023, which was just filed on February 14, 2024, and this has delayed the filing of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 will be filed on or before the 5th calendar day following the prescribed due date.

 

 
 

 

PART IV - OTHER INFORMATION

 

(1)

Name and telephone number of person to contact in regard to this notification
 
 

Terrence W. Norchi

  

(617)

  

431-2313
 

(Name)

  

(Area Code)

  

(Telephone Number)
 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
 
 

Yes ☒ NO ☐
 

 

 

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
 

Yes ☐ NO ☒
 
 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 
 

 

Arch Therapeutics, Inc.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:

February 14, 2023

By:

/s/ Terrence W. Norchi, M.D.
     

Terrence W. Norchi, M.D.

President, Chief Executive Officer